- Email: [email protected]
Subject Index for this special issue
Steroids 68 (2003) 1123–1124
Subject Index Abortion, 931 Affymetrix GeneChip1, 995 Androgen receptor, 1033, 1053 Angiogenesis, 849 Antiandrogens, 891 Antiglucocorticoid, 981 Antiprogestin, 1041, 1053, 1061, 1069, 1077, 1099 Antiproliferative, 1053 Apoptosis, 817 Aromatase inhibitor, 1077 Asoprisnil, 1019 Atherosclerosis, 941 Biologic activity, 879 Breakthrough bleeding, 1115 Breast cancer, 953 Cardiovascular system, 831 Cebus monkey, 1095 CEE, 921 Cell signaling, 761 Cervical ripening, 837 Chemical synthesis, 869 Clinical applications, 981 CNS, 891 Contraception, 891, 927, 1013, 1041, 1069, 1099 Cushing’s syndrome, 981 Cyproterone acetate, 965 Decidualization, 801, 849 Desogestrel, 965 Dienogest, 965 Drospirenone, 891 Dydrogesterone, 927 EGF, 817 Electroporation, 1085 Emergency contraception, 1095, 1107 Endometrial cancer, 801 Endometrial receptivity, 1069 Endometriosis, 801, 981, 1019 Endometrium, 801, 1013, 1033, 1053, 1061, 1115 Endothelial cells, 831 Erythropoietin, 1085 Estradiol, 921 Estrogen, 891, 941, 953, 973 Estrogen and progesterone receptors, 837 Etonogetrel, 965 Female reproductive tract, 1069 Flutamide, 1033 GABA receptors, 915 Gene transfer, 1085 Gestagens, 965
doi:10.1016/S0039-128X(03)00221-6
Glycoprotein Po, 825 Granulosa cells, 861 Granztme B, 861 Gynecological therapy, 1019 Hemostasis, 849 Human breast tissue, 789 IGF-I, 817 Implant, 907 Implantation, 801, 1077, 1077 In vivo model, 795 iNOS, 1077 Insulin-like growth-factor-I, 837 Interleukin-4, 931 Ishikawa endometrial cancer cell line, 795 Isoform, 771 Ki67 antigen, 789 Leiomyoma cells, 817 Levonorgestrel, 965, 1095, 1107 Male contraception, 965 Mammary gland, 779 Medroxyprogesterone, 965, 1115 Menopause, 941, 953 Menstrual cycle, 1013 Menstruation, 849 Metabolism, 879, 1005 Mice, 931 Mifepristone, 981, 1069, 1085, 1107, 1115 Mifepristone low dose, 1099 Molecular dynamics simulation, 869 Myoma, 981 Nestorone, 907 Neuroactive steroids, 825 19-Noresthisterone, 965 19-Norprogesterone, 907 Nuclear receptor, 869 Oocyte, 1041 Ovary, 861 Ovulation, 1013 Paracrine mechanism, 779 Peripheral myelin protein 22, 825 Pharmacokinetics, 879, 907 Pharmacology, 869, 1005 Placenta, 801 Plasmid-based, 1085 Potency, 879 PRA-910, 995 Pregnancy, 1077 Pregnancy termination, 981
1124
Subject Index / Steroids 68 (2003) 1123–1124
Preimplantation embryogenesis, 1041 Preterm birth, 1077 Progesterone, 771, 817, 825, 831, 849, 931, 995, 1013, 1061, 1077 Progesterone antagonist (PAs), 981, 1033, 1053, 1099 Progesterone function, 869 Progesterone receptor, 761, 795, 831, 869, 915, 931, 995 Progesterone receptor knockout, 779 Progesterone receptor modulator (PRMs), 981, 995, 1005 Progestin, 831, 879, 891, 915, 953, 965, 973 Progestogens, 941 Proliferation, 789 Rat, 1095 Receptor, 771 Receptors, 1115 Retrosteroid, 927 Risk assessment, 953 Schwann cells, 825 Selective progesterone receptor modulator (SPRMs), 981, 1019 Stem cells, 789
Steroid, 761, 795, 953, 995, 1005, 1013, 1033, 1069, 1085, 1095, 1107, 1115 Steroid receptors, 789, 915, 1061, 1099 Structure-based drug design, 869 Structure–function relationships, 879 Testosterone, 965 Tissue factor, 849 Transcription, 761 Transdermal gel, 907 Trimegestone, 915, 921 Tumor cell invasion and metastasis, 795 Tumorigenesis, 779 Tyrosine kinase, 761 Uterine fibroids, 1019 Vaginal ring, 907 Yuzpe regimen, 1095
Subject Index Abortion, 931 Affymetrix GeneChip1, 995 Androgen receptor, 1033, 1053 Angiogenesis, 849 Antiandrogens, 891 Antiglucocorticoid, 981 Antiprogestin, 1041, 1053, 1061, 1069, 1077, 1099 Antiproliferative, 1053 Apoptosis, 817 Aromatase inhibitor, 1077 Asoprisnil, 1019 Atherosclerosis, 941 Biologic activity, 879 Breakthrough bleeding, 1115 Breast cancer, 953 Cardiovascular system, 831 Cebus monkey, 1095 CEE, 921 Cell signaling, 761 Cervical ripening, 837 Chemical synthesis, 869 Clinical applications, 981 CNS, 891 Contraception, 891, 927, 1013, 1041, 1069, 1099 Cushing’s syndrome, 981 Cyproterone acetate, 965 Decidualization, 801, 849 Desogestrel, 965 Dienogest, 965 Drospirenone, 891 Dydrogesterone, 927 EGF, 817 Electroporation, 1085 Emergency contraception, 1095, 1107 Endometrial cancer, 801 Endometrial receptivity, 1069 Endometriosis, 801, 981, 1019 Endometrium, 801, 1013, 1033, 1053, 1061, 1115 Endothelial cells, 831 Erythropoietin, 1085 Estradiol, 921 Estrogen, 891, 941, 953, 973 Estrogen and progesterone receptors, 837 Etonogetrel, 965 Female reproductive tract, 1069 Flutamide, 1033 GABA receptors, 915 Gene transfer, 1085 Gestagens, 965
doi:10.1016/S0039-128X(03)00221-6
Glycoprotein Po, 825 Granulosa cells, 861 Granztme B, 861 Gynecological therapy, 1019 Hemostasis, 849 Human breast tissue, 789 IGF-I, 817 Implant, 907 Implantation, 801, 1077, 1077 In vivo model, 795 iNOS, 1077 Insulin-like growth-factor-I, 837 Interleukin-4, 931 Ishikawa endometrial cancer cell line, 795 Isoform, 771 Ki67 antigen, 789 Leiomyoma cells, 817 Levonorgestrel, 965, 1095, 1107 Male contraception, 965 Mammary gland, 779 Medroxyprogesterone, 965, 1115 Menopause, 941, 953 Menstrual cycle, 1013 Menstruation, 849 Metabolism, 879, 1005 Mice, 931 Mifepristone, 981, 1069, 1085, 1107, 1115 Mifepristone low dose, 1099 Molecular dynamics simulation, 869 Myoma, 981 Nestorone, 907 Neuroactive steroids, 825 19-Noresthisterone, 965 19-Norprogesterone, 907 Nuclear receptor, 869 Oocyte, 1041 Ovary, 861 Ovulation, 1013 Paracrine mechanism, 779 Peripheral myelin protein 22, 825 Pharmacokinetics, 879, 907 Pharmacology, 869, 1005 Placenta, 801 Plasmid-based, 1085 Potency, 879 PRA-910, 995 Pregnancy, 1077 Pregnancy termination, 981
1124
Subject Index / Steroids 68 (2003) 1123–1124
Preimplantation embryogenesis, 1041 Preterm birth, 1077 Progesterone, 771, 817, 825, 831, 849, 931, 995, 1013, 1061, 1077 Progesterone antagonist (PAs), 981, 1033, 1053, 1099 Progesterone function, 869 Progesterone receptor, 761, 795, 831, 869, 915, 931, 995 Progesterone receptor knockout, 779 Progesterone receptor modulator (PRMs), 981, 995, 1005 Progestin, 831, 879, 891, 915, 953, 965, 973 Progestogens, 941 Proliferation, 789 Rat, 1095 Receptor, 771 Receptors, 1115 Retrosteroid, 927 Risk assessment, 953 Schwann cells, 825 Selective progesterone receptor modulator (SPRMs), 981, 1019 Stem cells, 789
Steroid, 761, 795, 953, 995, 1005, 1013, 1033, 1069, 1085, 1095, 1107, 1115 Steroid receptors, 789, 915, 1061, 1099 Structure-based drug design, 869 Structure–function relationships, 879 Testosterone, 965 Tissue factor, 849 Transcription, 761 Transdermal gel, 907 Trimegestone, 915, 921 Tumor cell invasion and metastasis, 795 Tumorigenesis, 779 Tyrosine kinase, 761 Uterine fibroids, 1019 Vaginal ring, 907 Yuzpe regimen, 1095